Olaparib plus bevacizumab first-line maintenance in ovarian cancer : final overall survival results from the PAOLA-1/ENGOT-ov25 trial - PAOLA-1/ENGOT-ov25 investigators; Ray-Coquard, I.; Leary, A.; Pignata, S.; Cropet, C.; González-Martín, A.; Marth, C.; Nagao, S.; Vergote, I.; Colombo, N.; Mäenpää, J.; Selle, F.; et al. (2023)
Keywords: 3123 Gynaecology and paediatrics; 3122 Cancers